Zhang is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry, particularly in China.

Zhi Zhang
Latest news
-
LifeArc joins the REMEDi4ALL Consortium, a pioneering global platform shaping the future of drug repurposing
-
£1million partnership aims to develop new treatments for congenital muscular dystrophy
-
Tribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies